Medtronic statement to 7.30 Medtronic improves the health and lives of millions of people each year and is focussed on delivering these outcomes through appropriate access to medical technology. We believe healthcare professionals – in partnership with their patients – should have the right to choose the most appropriate medical device or treatment option. Volume discounts between suppliers and purchasers of the products, in this case hospitals, are standard commercial terms, not unique to the medtech industry and are commercial-inconfidence. These agreements currently help fund non-implantable medical technologies that are available in Australia and funded by Medicare, but not on the Prostheses List. This seeks to address a gap in the current system where all health insurers do not provide benefits for these technologies within their standard contracts with hospitals. Access to all available medical technologies preserve clinician choice, improve patient outcomes, reduce health system cost, and enhance value to privately insured patients. Medtronic is committed to making healthcare accessible and sustainable. We see an urgent need to reform the Prostheses List to include non-implantable technologies to improve the value of private health insurance and provide better access to innovative life-saving technologies.